Tichaona Mapangisana1, Rhoderick Machekano1,2, Vinie Kouamou3, Caroline Maposhere4, Kathy McCarty5, Marceline Mudzana5, Shungu Munyati4, Junior Mutsvangwa4, Justen Manasa6,7, Tinei Shamu8,9, Mampedi Bogoshi10, Dennis Israelski10, David Katzenstein4,11. 1. Division of Epidemiology and Biostatistics, Faculty of Medicine and Health Sciences, University of Stellenbosch, Cape Town, South Africa. 2. Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, United States of America. 3. Department of Medicine, University of Zimbabwe, Harare, Zimbabwe. 4. Biomedical Research and Training Institute, Harare, Zimbabwe. 5. Chidamoyo Christian Hospital, Karoi, Zimbabwe. 6. Department of Medical Microbiology, University of Zimbabwe, Harare, Zimbabwe. 7. African Institute for Biomedical Sciences and Technology, Harare, Zimbabwe. 8. Newlands Clinic, Harare, Zimbabwe. 9. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland. 10. Gilead Sciences Inc., Foster City, California, United States of America. 11. Department of Medicine, Stanford University School of Medicine, Stanford, California, United States of America.
Abstract
INTRODUCTION: Maintaining virologic suppression of children and adolescents on ART in rural communities in sub-Saharan Africa is challenging. We explored switching drug regimens to protease inhibitor (PI) based treatment and reducing nevirapine and zidovudine use in a differentiated community service delivery model in rural Zimbabwe. METHODS: From 2016 through 2018, we followed 306 children and adolescents on ART in Hurungwe, Zimbabwe at Chidamoyo Christian Hospital, which provides compact ART regimens at 8 dispersed rural community outreach sites. Viral load testing was performed (2016) by Roche and at follow-up (2018) by a point of care viral load assay. Virologic failure was defined as viral load ≥1,000 copies/ml. A logistic regression model which included demographics, treatment regimens and caregiver's characteristics was used to assess risks for virologic failure and loss to follow-up (LTFU). RESULTS: At baseline in 2016, 296 of 306 children and adolescents (97%) were on first-line ART, and only 10 were receiving a PI-based regimen. The median age was 12 years (IQR 8-15) and 55% were female. Two hundred and nine (68%) had viral load suppression (<1,000 copies/ml) and 97(32%) were unsuppressed (viral load ≥1000). At follow-up in 2018, 42/306 (14%) were either transferred 23 (7%) or LTFU 17 (6%) and 2 had died. In 2018, of the 264 retained in care, 107/264 (41%), had been switched to second-line, ritonavir-boosted PI with abacavir as a new nucleotide analog reverse transcriptase inhibitor (NRTI). Overall viral load suppression increased from 68% in 2016 to 81% in 2018 (P<0.001). CONCLUSION: Viral load testing, and switching to second-line, ritonavir-boosted PI with abacavir significantly increased virologic suppression among HIV-infected children and adolescents in rural Zimbabwe.
INTRODUCTION: Maintaining virologic suppression of children and adolescents on ART in rural communities in sub-Saharan Africa is challenging. We explored switching drug regimens to protease inhibitor (PI) based treatment and reducing nevirapine and zidovudine use in a differentiated community service delivery model in rural Zimbabwe. METHODS: From 2016 through 2018, we followed 306 children and adolescents on ART in Hurungwe, Zimbabwe at Chidamoyo Christian Hospital, which provides compact ART regimens at 8 dispersed rural community outreach sites. Viral load testing was performed (2016) by Roche and at follow-up (2018) by a point of care viral load assay. Virologic failure was defined as viral load ≥1,000 copies/ml. A logistic regression model which included demographics, treatment regimens and caregiver's characteristics was used to assess risks for virologic failure and loss to follow-up (LTFU). RESULTS: At baseline in 2016, 296 of 306 children and adolescents (97%) were on first-line ART, and only 10 were receiving a PI-based regimen. The median age was 12 years (IQR 8-15) and 55% were female. Two hundred and nine (68%) had viral load suppression (<1,000 copies/ml) and 97(32%) were unsuppressed (viral load ≥1000). At follow-up in 2018, 42/306 (14%) were either transferred 23 (7%) or LTFU 17 (6%) and 2 had died. In 2018, of the 264 retained in care, 107/264 (41%), had been switched to second-line, ritonavir-boosted PI with abacavir as a new nucleotide analog reverse transcriptase inhibitor (NRTI). Overall viral load suppression increased from 68% in 2016 to 81% in 2018 (P<0.001). CONCLUSION: Viral load testing, and switching to second-line, ritonavir-boosted PI with abacavir significantly increased virologic suppression among HIV-infectedchildren and adolescents in rural Zimbabwe.
Authors: Ragna S Boerma; Cissy Kityo; T Sonia Boender; Elizabeth Kaudha; Joshua Kayiwa; Victor Musiime; Andrew Mukuye; Mary Kiconco; Immaculate Nankya; Lilian Nakatudde; Peter N Mugyenyi; Michael Boele van Hensbroek; Tobias F Rinke de Wit; Kim C E Sigaloff; Job C J Calis Journal: J Trop Pediatr Date: 2017-04-01 Impact factor: 1.165
Authors: Vinie Kouamou; Justen Manasa; David Katzenstein; Alan M McGregor; Chiratidzo E Ndhlovu; Azure T Makadzange Journal: AIDS Date: 2019-09-01 Impact factor: 4.177
Authors: Mark A Boyd; Cecilia L Moore; Jean-Michel Molina; Robin Wood; Juan S Madero; Marcelo Wolff; Kiat Ruxrungtham; Marcelo Losso; Boris Renjifo; Hedy Teppler; Anthony D Kelleher; Janaki Amin; Sean Emery; David A Cooper Journal: Lancet HIV Date: 2015-01-20 Impact factor: 12.767
Authors: Xavier Saez-Llorens; Elizabeth Castaño; Mobeen Rathore; Joseph Church; Jaime Deville; Aditya Gaur; Dora Estripeaut; Kirsten White; Sarah Arterburn; Jeffrey V Enejosa; Andrew K Cheng; Steven L Chuck; Martin S Rhee Journal: Pediatr Infect Dis J Date: 2015-04 Impact factor: 2.129
Authors: Marielle Bemelmans; Saar Baert; Eric Goemaere; Lynne Wilkinson; Martin Vandendyck; Gilles van Cutsem; Carlota Silva; Sharon Perry; Elisabeth Szumilin; Rodd Gerstenhaber; Lucien Kalenga; Marc Biot; Nathan Ford Journal: Trop Med Int Health Date: 2014-05-28 Impact factor: 2.622
Authors: Anna Grimsrud; Helen Bygrave; Meg Doherty; Peter Ehrenkranz; Tom Ellman; Robert Ferris; Nathan Ford; Bactrin Killingo; Lynette Mabote; Tara Mansell; Annette Reinisch; Isaac Zulu; Linda-Gail Bekker Journal: J Int AIDS Soc Date: 2016-12-01 Impact factor: 5.396